% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • losinglunch losinglunch Jul 11, 2013 5:15 PM Flag

    Stanford research on CD47

    Any of you following their work? Is this a possible "cure-all" or "cure-most" like they're saying? Is SGEN or anyone else going after this the same way as Stanford?

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      The research being produced by the Irv Weissman lab is showing some outstanding promise in murine models. If this work is also being conducted outside of academia, I don't think the players have as yet shown their hand. SGEN's ADC collaboration pipeline is loaded with wild cards, however, and the "undisclosed ADC's" listed w/ Bayer, Pfizer, Astellas, and GSK all may have CD-47/ TSP-1/ SIRP inhibitor/ activator potential. Stanford's claim to initiate human trials by mid-2014 may tease some commercial research into the spotlight. Best to keep an eye out.

53.29-2.04(-3.69%)Sep 29 4:00 PMEDT